Table 3. Univariate and multivariable Cox regression analyses.
| Univariate analysis | Multivariate analysis | |||||||
|---|---|---|---|---|---|---|---|---|
| n | HR | 95% CI | P-value | Coefficient | HR | 95% CI | P-value | |
| Model cohort (n = 424) | ||||||||
| Age(year) | 424 | 1.022 | 1.005–1.038 | 0.010 | 0.025 | 1.025 | 1.007–1.044 | 0.007 |
| Gender (Male/Female) | 424 | 1.112 | 0.752–1.645 | 0.595 | −0.101 | 0.904 | 0.595–1.373 | 0.636 |
| AJCC PT (T4,T3/T2,T1) | 424 | 2.926 | 1.356–6.318 | 0.006 | 1.161 | 3.193 | 1.248–8.165 | 0.015 |
| AJCC PN (N2,N1/N0) | 424 | 2.506 | 1.683–3.733 | <0.001 | −0.551 | 0.576 | 0.218–1.524 | 0.267 |
| AJCC PM (MX,M1/M0) | 418 | 2.962 | 1.985–4.419 | <0.001 | 0.707 | 2.029 | 1.284–3.205 | 0.002 |
| AJCC stage (IV,III/II,I) | 413 | 2.841 | 1.869–4.317 | <0.001 | 1.233 | 3.433 | 1.157–10.187 | 0.026 |
| Nine-lncRNA prognostic signature (High/Low) | 424 | 4.790 | 2.974–7.713 | <0.001 | 1.513 | 4.539 | 2.722–7.571 | <0.001 |
| Validation cohort (n = 424) | ||||||||
| Age(year) | 424 | 1.017 | 1.002–1.033 | 0.032 | 0.031 | 1.031 | 1.012–1.050 | 0.001 |
| Gender (Male/Female) | 424 | 1.051 | 0.720–1.535 | 0.797 | −0.213 | 0.808 | 0.538–1.214 | 0.306 |
| AJCC PT (T4,T3/T2,T1) | 424 | 8.353 | 2.646-26.368 | <0.001 | 3.079 | 21.729 | 2.988–158.025 | 0.002 |
| AJCC PN (N2,N1/N0) | 424 | 2.253 | 1.528–3.323 | <0.001 | −0.526 | 0.591 | 0.260–1.346 | 0.211 |
| AJCC PM (MX,M1/M0) | 418 | 2.347 | 1.577–3.493 | <0.001 | 0.570 | 1.769 | 1.107–2.827 | 0.017 |
| AJCC stage (IV,III/II,I) | 414 | 2.741 | 1.817–4.134 | <0.001 | 1.231 | 3.425 | 1.317–8.905 | 0.012 |
| Nine-lncRNA prognostic signature (High/Low) | 424 | 4.577 | 2.926–7.161 | <0.001 | 1.515 | 4.551 | 2.806–7.383 | <0.001 |
Notes.
- AJCC
- the American Joint Committee on Cancer
- HR
- hazard ratio
- CI
- confidence interval
The median of nine-lncRNA prognostic signature score was used as the cutoff value to stratify colorectal patients into high risk group and low risk group.